Compared with other glands in the body, the adult human breast is unique in being invested in an abundance of adipose tissue. This is most marked in older women, the ratio of breast adipose to glandular tissue increasing with age (Preschtel, 1979) .
The role of mammary adipose tissue is not fully understood, but in mice the mammary fat pad appears to be essential not only for the normal growth of the mammary gland but also for the development of hyperplastic lesions and cancers (De Ome et al., 1959) . Since oestrogens are heavily implicated in the aetiology of human breast cancer (McMahon et al., 1973) it may be pertinent that adipose tissue throughout the body is capable of synthesising oestrogens (Nimrod & Ryan, 1975; Perel & Killinger, 1979; Folkerd et al., 1982; Forney et al., 1981; Deslypere et al., 1985) . Factors influencing such peripheral aromatisation are largely unknown, although levels are known to vary between individuals and different body sites (Perel & Killinger, 1979) .
The object of the present study was to measure aromatase activity in breast adipose tissue and to compare levels in patients with breast cancer with those in women with benign lesions of the breast.
Materials and methods

Chemicals
1#3HA4 androstenedione was synthesised from 1#2fpHA4 androstenedione (56.0 Ci mmol-1, New England Nuclear) using the method of Berkovitz et al. (1984) .
Radio-inert A4 androstenedione, glucose 6 phosphate dehydrogenase (Type XI), NAD (grade V), glucose 6 phosphate (disodium salt), ATP (disodium salt), NADP (monosodium salt), nicotinamide and activated charcoal were obtained from Sigma Chemical Co. Ltd., Poole, Dorset. NE260 Scintillant was obtained from Nuclear Enterprises Ltd., Edinburgh, and bovine serum albumin from Armour Pharmaceuticals, Eastbourne. Other chemicals and solvents were obtained from BDH Chemicals Ltd., Poole.
Patients
Adipose tissue was obtained from breast cancer patients treated either by mastectomiy or wide local excision and from patients having excision biopsies performed for benign conditions. Details of the patients studied are shown in Table I . Patients were considered to be post-menopausal if more than 3 years had elapsed since their last menstrual period. Histological details of the associated breast biopsies are given in Table II Nimrod & Ryan (1975) . Adipose tissue (2 g) was homogenised by hand in a glass-to-glass homogenizer with 2 ml of 0.1 M phosphate buffer (pH 7.4) and centrifuged at 800 g for 5 min. The resultant supernatant was separated from the upper layer of solid lipid and the lower layer of cell debris using a pasteur pipette and centrifuged at 100,000g for 1 h. The resulting pellet (particulate fraction) was resuspended in phosphate buffer (600 p1) and assayed for aromatase activity.
Protein estimation
The protein concentration of the particulate fraction was measured by the method of Bradford (1976) . Concentrations varied from 0.5-6.0 mgml-P and no significant difference was evident between fractions from cancer and non-cancer patients.
Br. J. Cancer (1987), 56, 601-604 Aromatase assay The assay was based on the measurement of 3H water released during the conversion of 1J3HA4 androstenedione to oestrogen (Frieden et al., 1968 
Results
Oestrogen biosynthesis was detected in all samples of breast adipose tissue examined with activities varying from 3.1 to 114 fmol oestrogen produced mg protein-l h-1 (units). As is shown in Figure 1 the median activity in tissue from breast cancer patients (27.0 units) was more than two-fold higher than that in samples from women with benign conditions (12.3 units). The difference between the groups was significant by the Wilcoxon Rank test (P<0.0001).
As measurements were performed on consecutive patients from whom it was possible to obtain sufficient tissue for analysis, the groups have not been matched in any respect and therefore correlations have been made with other factors which might influence oestrogen biosynthesis. The relationship with age of the subjects is plotted separately in Figure 2 for patients with either benign or malignant lesions. In neither group of patients was there an obvious relationship between levels of activity and age, although a tendency was apparent for the highest levels of aromatase to be found in breast fat from cancer patients between the ages of 40 and 55 years. The effect of menopausal status on aromatase activity in breast fat from cancer patients is shown in Figure  3 . The median value (32 units) in pre-and peri-menopausal patients was higher than that in post-menopausal patients (23 units), but the difference was not statistically significant. Meaningful analysis of the benign group was not possible because of the small number of post-menopausal women with non-malignant breast conditions. Since there were marked differences between the cancer and benign groups in terms of both age and menopausal status, it was of interest to compare results using pre-and peri-menopausal patients only, thus minimising the age discrepancy between the groups. As is shown in Figure 4 , aromatase activity remained significantly higher in the cancer group (P<0.OO0 1). The results were also analysed with regard to height, weight, obesity (Quetlet index, wt/ht2), parity, age at menarche, age at first full term pregnancy, and family history of breast cancer but no trends were detected (results not shown). Furthermore, in the cancer group there was no relationship between aromatase activity and tumour type, size, oestrogen receptor protein content or clinical stage.
Discussion
Adipose tissue is an important site of oestrogen biosynthesis and, especially in post-menopausal women, such peripheral activity contributes significantly to oestrogens in the circulation (Grodin et al., 1973) . However in view of the relative abundance of adipose tissue within the breast, oestrogen biosynthesis in mammary adipose tissue may be of more relevance to events occuring locally within the breast. It is pertinent therefore that the present study demonstrates the potential for oestrogen biosynthesis in all specimens of breast adipose tissue examined. Levels were of a similar Figure 3 Aromatase activity in breast adipose tissue from women with breast cancer related to menopausal status (postmenopausal >3 years since last menstruation). The horizontal bars denote the median activity for the two groups. The difference between the two groups is not statistically significant. magnitude to those reported by others for adipose tissue from various body sites (Nimrod & Ryan, 1975; Perel & Killinger, 1979; Folkerd et al., 1982; Forney et al., 1981; Deslypere et al., 1985) .
An important observation was that despite the large variation in levels of aromatase activity between different specimens of adipose tissue, activity was significantly higher in tissue obtained from women with breast cancer compared Cancer Benign
Pre-and peri-menopausal women (a-3 yr since LMP) Figure 4 Aromatase activity in breast adipose tissue from preand peri-menopausal women with breast cancer (0, n=30) or benign breast disease (O, n=29). The horizontal bars denote the median activity for the two groups. The difference between the two groups is significant by the Wilcoxon rank test.
with that in adipose tissue from women with benign lesions. Others have failed to detect such a difference (Nimrod & Ryan, 1975; Perel & Killinger, 1979) but have studied very small numbers of patients. The larger study of Beranek and co-workers (1984) also reported no significant difference between cancer and control patients but employed less sensitive assay conditions utilising soluble rather than particulate fractions [the latter increase the sensitivity of (Nimrod & Ryan, 1975) ]. Nevertheless aromatase activity was detected in 82% of cancer cases compared with only 50% of those with benign conditions suggesting a trend towards enhanced aromatase activity in adipose tissue from breast cancer patients. There are two possible explanations for the presence of higher aromatase in breast adipose tissue from breast cancer patients, namely, either malignant tumours are capable of stimulating aromatase activity in surrounding tissues or regionally enhanced aromatase activity in adipose tissue produces a local environment which promotes malignant growth at that site.
With regard to the former possibility recent data suggest that growth factors enhance aromatase activity in peripheral tissues (McNeill et al., 1986) . These include factors which may be produced in a paracrine manner by tumours and preliminary results indicate that the addition of extracts from breast cancers to cultures of adipose tissue may stimulate oestrogen biosynthesis (Reed, 1986, personal communication) .
Since oestrogens are heavily implicated in the promotion of breast cancer (Lacassagne, 1932; Symmers, 1968) , local areas of enhanced oestrogen production might be expected to encourage development of tumour foci at these favourable sites. If this is the case one would expect a particular association between high aromatase activity in adipose tissue and oestrogen receptor positive tumours which are more likely to be oestrogen responsive. However such an association was not found in the present study.
As breast cancers in general have higher aromatase activity than adipose tissue (Abul-Haji et al., 1979; Perel et al., 1980 ) the higher activity in adipose tissue from breast cancer patients could also be due to the presence of micrometastatic deposits of malignant cells within the adipose tissue. Whilst this possibility cannot be completely excluded, portions of fat adjacent to that used for the aromatase assay were not shown to be involved microscopically with cancer. Although levels of aromatase activity were higher in fat from breast cancer patients, a large range of values was found in patients with and without malignant breast disease.
It is clear therefore that other factors must influence the aromatase system. Statistically significant relationships were not observed between aromatase activity and age or menopausal status of the patients from whom the samples were obtained, although the highest levels of activitiy were observed in women aged between 40 and 55. This trend is similar to that noted in a study of abdominal adipose tissue (Folkerd et al.,. 1982) . However in view of the relative excess of pre-menopausal women in our benign group as compared with cancer patients and the reports of others that peripheral aromatase increases with age (Forney et al., 1981; Cleland et al., 1985) , the data was reanalysed excluding postmenopausal women. The difference in aromatase activity between the cancer patients and the non-malignant group remained highly significant, so it is therefore extremely unlikely to be an age related phenomenon.
As we also failed to detect significant relationships between aromatase activity and various factors associated with excess risk of breast cancer such as height, weight, obesity, parity, age at menarche, age at first full term pregnancy, and family history of breast cancer, the differences between cancer and control patients are unlikely to be due to any excess of these risk factors in the cancer group. Factors which influence the inherent level of aromatase in breast adipose tissue still therefore require to be identified. However in view of the central role of oestrogen in both the aetiology and continued growth of endocrine sensitive tumours, the identification of such factors and the mechanisms by which they act may lead to the capacity to modify the local endocrine environment within the breast and could ultimately prove to be of value in the clinical managment of breast cancer.
